Robert W. Baird Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective increased by Robert W. Baird from $160.00 to $209.00 in a research note released on Tuesday morning,Benzinga reports. They currently have an outperform rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on JAZZ. Morgan Stanley increased their target price on Jazz Pharmaceuticals from $185.00 to $205.00 and gave the company an “overweight” rating in a report on Monday. JPMorgan Chase & Co. reduced their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. Bank of America lifted their price objective on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist Financial boosted their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Finally, Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $195.07.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $180.52 on Tuesday. Jazz Pharmaceuticals has a 1-year low of $95.49 and a 1-year high of $182.99. The company has a market capitalization of $10.97 billion, a P/E ratio of -26.82, a PEG ratio of 8.49 and a beta of 0.29. The business has a 50 day moving average price of $135.92 and a 200 day moving average price of $121.19. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, topping the consensus estimate of $5.87 by $2.26. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same period in the previous year, the firm earned $6.54 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. Sell-side analysts expect that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director directly owned 429,973 shares of the company’s stock, valued at $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold 11,500 shares of company stock worth $1,525,280 over the last 90 days. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. CWM LLC lifted its holdings in shares of Jazz Pharmaceuticals by 56.2% during the 1st quarter. CWM LLC now owns 1,259 shares of the specialty pharmaceutical company’s stock valued at $156,000 after acquiring an additional 453 shares in the last quarter. Y Intercept Hong Kong Ltd raised its position in Jazz Pharmaceuticals by 269.5% in the first quarter. Y Intercept Hong Kong Ltd now owns 9,721 shares of the specialty pharmaceutical company’s stock valued at $1,207,000 after purchasing an additional 7,090 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Jazz Pharmaceuticals during the first quarter worth about $10,900,000. KLP Kapitalforvaltning AS boosted its position in shares of Jazz Pharmaceuticals by 1.8% in the first quarter. KLP Kapitalforvaltning AS now owns 17,300 shares of the specialty pharmaceutical company’s stock worth $2,148,000 after buying an additional 300 shares during the period. Finally, Readystate Asset Management LP grew its stake in shares of Jazz Pharmaceuticals by 7.7% in the first quarter. Readystate Asset Management LP now owns 22,869 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after buying an additional 1,635 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.